… Data on cardiovascular events and mortality in the included trials are shown in Table 2. …
analyses of RCTs evaluating the effects of rosiglitazone for MI, heart failure, and cardiovascular …

… on cardiovascular risk of rosiglitazone compared with a basal insulin drug. The main outcomes
included myocardial infarction, heart failure, stroke, cardiovascular … to rosiglitazone and a …

… rosiglitazone treated patients. There was no evidence of an association between rosiglitazone
and death due to cardiovascular … of heart failure conferred by rosiglitazone treatment was …

… heightened the debate about the usefulness and limitations of meta-analysis … meta-analyses
for harmful cardiovascular events, with special attention to the rosiglitazone meta-analyses, …

… Reviewers within the FDA Office of Surveillance and Epidemiology calculated the number
of major CV events potentially attributable to rosiglitazone therapy from 1999 to 2006, …

… assessing the effects of rosiglitazone, compared with … meta-analyses [1], [7]. Considering
that the mechanisms underlying the possible negative effect of rosiglitazone on cardiac events …

… However, a recent meta-analysis of 42 trials comparing rosiglitazone with placebo or …
rosiglitazone was associated with an increased risk of myocardial infarction and cardiovascular …

… of rosiglitazone and pioglitazone in the present meta-analysis … from any cause, but the
number of events in head-to-head … of rosiglitazone and pioglitazone on cardiovascular events. …

… This meta-analysis compared the cardiovascular risks of rosiglitazone and pioglitazone
based on a total of eight retrospective cohort studies. The risk of all three outcomes—MI, heart …

… of rosiglitazone and pioglitazone on cardiovascular outcomes (… adverse cardiovascular
events with rosiglitazone compared … likelihood of cardiovascular harm if rosiglitazone was used …